How much does a GLP-1 cost without insurance in 2026?

If you are paying out of pocket, the headline “$1,000-plus a month” figure you see for GLP-1 medicines is the list price, not what most cash-pay patients actually pay in 2026. The real out-of-pocket number depends on which branded product you buy, which dose you are on, and whether you use the manufacturer’s own self-pay pharmacy. This page walks through the current prices, pinned to each drugmaker’s published pricing.

How much does a GLP-1 cost without insurance in 2026?

Without insurance, expect to pay roughly $299 to $499 per month for a branded GLP-1 in 2026 when you buy directly from the manufacturer’s cash self-pay program, versus a list price above $1,000 per month at a standard retail pharmacy. The four branded products most people ask about are Wegovy and Ozempic (both semaglutide) and Zepbound and Mounjaro (both tirzepatide). Here is the current self-pay landscape:

The cash prices above come straight from the manufacturers’ self-pay programs. The “over $1,000/mo” list figures for Zepbound and Mounjaro are our reading of Lilly’s published pricing, because Lilly does not surface a single monthly list number the same way Novo Nordisk does. For a fuller breakdown of coverage and savings, see our guide to GLP-1 cost, insurance, and savings.

List price vs. cash price: why the two numbers look so different

The list price is the original figure a manufacturer sets before any discount or rebate, and most people do not pay it. Novo Nordisk states plainly that list price “is the original price set for a medication by a manufacturer before any discounts or rebates are applied. However, most people don’t pay list price if they have health insurance” (NovoCare). For someone without insurance, the practical number is the manufacturer’s cash self-pay price, which bypasses insurance entirely and is often less than half the list price. That is why a Wegovy pen listed at $1,349.02 per package can cost $299 per month through NovoCare Pharmacy self-pay (NovoCare).

How much does semaglutide (Wegovy and Ozempic) cost without insurance?

Semaglutide costs about $149 to $499 per month without insurance in 2026, depending on which branded product and dose you buy. For weight management, Wegovy has a list price of $1,349.02 per package, but its self-pay cash price is $299 per month for the injectable pen and $149 per month for the oral pill (NovoCare). In March 2026 the FDA approved a higher-dose Wegovy HD (semaglutide 7.2 mg), now the highest FDA-approved weight-management dose, based on the STEP UP trial’s roughly 20.7% mean weight loss (Novo Nordisk); the self-pay figures above reflect Novo Nordisk’s standard Wegovy pen. For type 2 diabetes, Ozempic carries a list price of $1,027.51 per pen, while its self-pay price is $349 per month for the 0.25 mg, 0.5 mg, and 1 mg doses and $499 per month for the 2 mg dose; new self-pay patients pay $199 for each of their first two monthly fills through December 31, 2026 (NovoCare). Wegovy is FDA-approved for chronic weight management (DailyMed) and Ozempic is FDA-approved for type 2 diabetes (DailyMed), so which one a provider considers depends on your clinical picture, not just price. PeptideAgent’s semaglutide cost page follows the same channels, along with the Medicare GLP-1 Bridge copay and the negotiated Medicare price that starts in 2027.

How much does tirzepatide (Zepbound and Mounjaro) cost without insurance?

Tirzepatide costs about $299 to $499 per month without insurance in 2026 through the manufacturer’s self-pay programs. Zepbound single-dose vials, ordered through LillyDirect, are priced at $299 per month for the 2.5 mg dose, $399 per month for the 5 mg dose, and $449 per month for the 7.5 mg through 15 mg doses, effective February 23, 2026, as long as each refill is purchased within 45 days of the previous one (Lilly). Miss that 45-day window and the price rises to the standard self-pay level: $499 for 7.5 mg and $699 for the 10 mg, 12.5 mg, and 15 mg doses (Lilly). Mounjaro, the type 2 diabetes version of tirzepatide (DailyMed), is available to self-pay patients for as low as $499 for a one-month fill (Lilly).

Can a savings card lower the cost if you have insurance?

A manufacturer savings card can cut the monthly cost to as little as $25 for people with commercial insurance, but government-insured patients are excluded. For semaglutide, the Wegovy savings offer lets eligible commercially insured patients “pay as little as $25” per month, with “a max savings of $100/month” (NovoCare); the Ozempic savings offer is structured the same way, as little as $25 per month up to $100 in monthly savings (NovoCare). For tirzepatide, the Mounjaro savings card lets commercially insured patients with a covered prescription pay “as little as $25 for up to a 3-month” fill, with a maximum annual savings of up to $1,950 (Lilly). All of these cards exclude people covered by Medicare, Medicaid, or other government programs, so if you are uninsured or government-insured, the self-pay cash prices above are usually the relevant numbers.

Is compounded semaglutide a cheaper option in 2026?

Compounded semaglutide is no longer the routine low-cost route it was during the shortage, and the manufacturer self-pay programs above are now the main way to pay less without insurance. The FDA determined the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage on October 2, 2024, which ended the basis for widespread compounding (FDA). A low sticker price also buys less than it seems: compounded versions are not FDA-approved, have not been tested in the trials behind the brands, are often measured by hand from multi-dose vials, and have been linked to dosing errors and hundreds of adverse event reports (FDA, concerns with unapproved GLP-1 drugs). The FDA lists prices that seem too good to be true as one of its red flags for online sellers. A licensed provider may still consider a patient-specific compounded preparation where there is a documented clinical reason the approved product cannot be used, but that is a clinical decision, not a discount. The same caution applies to the investigational drugs now listed online; our retatrutide cost explainer covers why those prices vary so widely.

Why is GLP-1 insurance coverage so inconsistent?

Coverage varies widely because plans can treat weight-management drugs differently from diabetes drugs: a plan may cover Ozempic or Mounjaro for type 2 diabetes but exclude Wegovy or Zepbound for weight loss, and some employer plans exclude weight-loss drugs entirely. By federal statute, Medicare Part D does not cover a drug used only for weight loss (CMS). That patchwork is exactly why so many people end up paying cash, and why the manufacturer self-pay prices have become the reference point for anyone shopping without coverage. If your plan excludes these medicines, you are effectively a cash-pay patient even if you are insured.

What should you budget, and what is the next step?

Plan on roughly $299 to $499 per month for a branded GLP-1 without insurance in 2026, plus the separate cost of a provider visit and any lab work. Introductory offers can lower your first months, and a savings card can help if you have commercial coverage, but the durable monthly number for most cash-pay patients sits in that $299 to $499 range. Which medicine and dose fit you is a clinical question that depends on your health history and goals, not price alone.

See what a licensed provider recommends for your weight goals. A provider reviews your health history and decides whether a GLP-1 is appropriate for you, and not everyone is a candidate. You can also read our companion explainer on what compounded semaglutide is and how it compares.